LIVE

CRL

Charles River Laboratories International, Inc.

CRL

NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $11.0B

$230.69

▲ +0.70%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$144.26 - $236.62

P/E

-61.35

Fwd P/E

20.98

Beta

1.45

Div Yield

0.00%

Avg Vol

883.5K

Shares Out

49.3M

Mkt Cap

$11.0B

Price action

Price chart

Up 45.5% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Comprehensive end-to-end research services
  • Extensive global laboratory network
  • Deep scientific expertise
  • Established relationships with major pharmaceutical companies
▼

Bear Case

1 risk

  • Average volatility.

Growth

Turning profitable

Increasing pharmaceutical R&D spending

Value

Attractively priced below Life Sciences Tools peer average

Momentum

Hot

+31.7% over 3m

Quality

Stable

Strong fundamentals

Dividend

None

No dividend

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 5, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of $2.06 vs $1.96 consensus (+5.1% surprise). Revenue of $995.8M vs $977.5M expected (+1.9%). Beat on both top and bottom lines.

EPS beat +5.1%
Rev beat +1.9%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+5.1%

Next: May 5, 2026

Revenue trend · last 8Q

—

—

-1%

-3%

+1%

-0%

-1%

+1%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$1.0B

$1.0B

$1.0B

$984.2M

$1.0B

$1.0B

$994.2M

$995.8M

Margins · last 8Q

Gross

—

Operating

—

Profit

-1.5%

View full earnings history →

Wall Street consensus

9 analysts · 67% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

6

67%

Hold

3

33%

Sell

0%

Median Price Target

$215.00

▼ -6.8% vs $230.69

Low $192.00
Median $215.00
High $220.00

Latest: Morgan Stanley · Jun 17, 2026

6 analysts covering

View full analyst page →

vs Industry

How CRL stacks vs Medical - Diagnostics & Research

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.